# AP20 Rec'd FCT/PTO 17 APR 2006

#### IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No.	:	PCT/EP2004/010397
International Filing Date	:	16 September 2004 (16.09.2004)
Priority Date(s) Claimed	:	18 October 2003 (18.10.2003)
Applicant(s) (DO/EO/US)	:	Robert HAMMOND-SMITH

Title: BARRIER COATING COMPOSITION CONTAINING A LIQUID CRYSTALLINE POLYMER AS WELL AS A DEVICE CONTAINING THIS BARRIER COATING COMPOSITION

### INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§  $1.56,\,1.97$  and 1.98 as follows:

### Timing and Fees

	-	
⊴		37 C.F.R. $\S$ 1.97(b), no fee or statement is required for filing this information sure statement is filed:
		within three months of the filing date of a national application other than a CPA under $\S$ 1.53(d);
	$\boxtimes$	within three months of the actual filing date of the national phase of a PCT application; $\ensuremath{OR}$
		before the mailing of a first substantive office action (including after filing of an RCE).
		37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods ied in 37 C.F.R. § 1.97(b), but before the mailing date of:

a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and

		is acco	mpanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
			R. § 1.97(d), this information disclosure statement is filed after the mailing owing actions which have not been withdrawn:
		a final	action under 37 C.F.R. § 1.113;
		termina	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
		OR a n	otice of allowance under 37 C.F.R. § 1.311;
	AND i	s filed o	n or before payment of the issue fee; AND is accompanied by:
			ement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 0 under 37 C.F.R. § 1.17(p).
Statem	nents Ur	nder 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R.§ 1.56(c) more than three months prior to the filing date of the information disclosure statement.
Cited !	Materia	<u>ls</u>	
		ancesto	of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form y the applicant; see 37 C.F.R. § 1.98(d).
	$\boxtimes$		of materials listed but not attached were cited in an international search dated January 20, 2005.
		Not rec	quired by 37 CFR § 1.98.
		Copies	of the materials listed are attached (except for the foregoing).

## 10/576011

## IAP20 Rec'6 FCT/PTO 17 APR 2006

### Non-English Language References $\boxtimes$ An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s). A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below: document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document defining the general state of the art A = non-written disclosure $\Omega =$ P =intercalated document T= document cited to understand the theory or principle underlying the invention E =patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date D =cited in the application L =cited for another reason &= publication of member of same patent family Translation of other relevant information on foreign search report Other Information

## Payment of Fees Duc (If Any): A check for \$\_\_\_\_ covering the fee identified above is attached.

## AP20 Rec'6. JAPTO 17 APR 2006

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza I 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333 Faesimile: (703) 243-6410

Attorney Docket No.: MERCK-3152

Date: April 17, 2006

AJZ:ssr

Sheet

PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)

of

Complete if Known, USNP-of PCT/EP2004/01039/ Application Number Filing Date 16 September 2004 (16.09.2004) Robert HAMMOND-SMITH First Named Inventor Group Art Unit unknown Examiner Name unknown Attorney Docket Number MFRCK-3152

			U.S. P	ATENT DOCUMENTS	
		U.S. Patent Docum	nent		Date of Publication of Cited Document
Examiner Initials *	Cite No.1	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	MM-DD-YYYY
	001	5,707,691	Α	PLESTER, ET AL.	01-13-1998
	002	6,179,818	B1	KYDONIEUS, ET AL.	01-30-2001
	003	5,288,529	Α	HARVEY, ET AL.	02-22-1994
	004	6,099,758	Α	VERRALL, ET AL.	08-08-2000
	005	6,136,225	Α	MEYER, ET AL.	10-24-2000
	006	2003/0080321	A1	FARRAND, ET AL.	05-01-2003
	007	2003/0190437	A1	VERRALL, ET AL.	10-09-2003
					1

FOREIGN PATENT DOCUMENTS								
		Foreign Petent Document				Date of Publication of	Pages, Columns, Lines, Where Relevent	
Examiner Initials*	Cite No.1	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	7*
	008	GB	2,379,931	Α	MERCK PATENT GMBH	03-26-2003		
	009	GB	2,311,289	A	MERCK PATENT GMBH	09-24-1997		
	010	GB	2,329,899	A	MERCK PATENT GMBH	04-07-1999		004
	011	wo	97/00600	Α	BASF AG	01-09-1997		005
	012	EP	1,247,797	A	MERCK PATENT GMBH	10-09-2002		006
	013	wo	98/04651	Α	MERCK PATENT GMBH	02-05-1998		007
	014	wo	94/29386	A	SUOKAS, ET AL.	12-22-1994		

Examiner Signature	/Michele Jacobson/	Date Considered	06/12/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hotz Statement: The form is astinated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete his form should be sent to the Other Information Officer. U.S. Patient and Trademarks

Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patients, P.O.
80x 1493, Maxandria V. 22313-1450.